[go: up one dir, main page]

SE9703414D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9703414D0
SE9703414D0 SE9703414A SE9703414A SE9703414D0 SE 9703414 D0 SE9703414 D0 SE 9703414D0 SE 9703414 A SE9703414 A SE 9703414A SE 9703414 A SE9703414 A SE 9703414A SE 9703414 D0 SE9703414 D0 SE 9703414D0
Authority
SE
Sweden
Prior art keywords
pct
sec
new compounds
date
pub
Prior art date
Application number
SE9703414A
Other languages
English (en)
Inventor
Nils-Aake Bergman
Ambra Thomas D
Garry Pilling
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9703414A priority Critical patent/SE9703414D0/sv
Publication of SE9703414D0 publication Critical patent/SE9703414D0/sv
Priority to ZA988353A priority patent/ZA988353B/xx
Priority to CN98811336A priority patent/CN1279666A/zh
Priority to SK360-2000A priority patent/SK3602000A3/sk
Priority to CA002303528A priority patent/CA2303528A1/en
Priority to DE69809782T priority patent/DE69809782T2/de
Priority to AU92889/98A priority patent/AU9288998A/en
Priority to AT98945708T priority patent/ATE228500T1/de
Priority to JP2000512808A priority patent/JP2001517651A/ja
Priority to BR9812492-7A priority patent/BR9812492A/pt
Priority to EP98945708A priority patent/EP1017672B1/en
Priority to TR2000/00785T priority patent/TR200000785T2/xx
Priority to KR1020007003029A priority patent/KR20010024220A/ko
Priority to US09/171,779 priority patent/US6127414A/en
Priority to PCT/SE1998/001686 priority patent/WO1999015498A1/en
Priority to IL13499398A priority patent/IL134993A0/xx
Priority to PL98339617A priority patent/PL339617A1/xx
Priority to EEP200000171A priority patent/EE200000171A/xx
Priority to ARP980104740A priority patent/AR017138A1/es
Priority to IS5410A priority patent/IS5410A/is
Priority to NO20001483A priority patent/NO20001483L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9703414A 1997-09-23 1997-09-23 New compounds SE9703414D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds
ZA988353A ZA988353B (en) 1997-09-23 1998-09-11 New NPY antagonists
EEP200000171A EE200000171A (et) 1997-09-23 1998-09-21 Uued NPY antagonistid
JP2000512808A JP2001517651A (ja) 1997-09-23 1998-09-21 新しいnpy拮抗剤
TR2000/00785T TR200000785T2 (tr) 1997-09-23 1998-09-21 Yeni NPY antagonistleri.
CA002303528A CA2303528A1 (en) 1997-09-23 1998-09-21 New npy antagonists
DE69809782T DE69809782T2 (de) 1997-09-23 1998-09-21 Npy antagonisten
AU92889/98A AU9288998A (en) 1997-09-23 1998-09-21 New npy antagonists
AT98945708T ATE228500T1 (de) 1997-09-23 1998-09-21 Npy antagonisten
CN98811336A CN1279666A (zh) 1997-09-23 1998-09-21 新的npy拮抗剂
BR9812492-7A BR9812492A (pt) 1997-09-23 1998-09-21 Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
EP98945708A EP1017672B1 (en) 1997-09-23 1998-09-21 New npy antagonists
SK360-2000A SK3602000A3 (en) 1997-09-23 1998-09-21 New npy antagonists
KR1020007003029A KR20010024220A (ko) 1997-09-23 1998-09-21 신규한 npy 길항제
US09/171,779 US6127414A (en) 1997-09-23 1998-09-21 NPY antagonists
PCT/SE1998/001686 WO1999015498A1 (en) 1997-09-23 1998-09-21 New npy antagonists
IL13499398A IL134993A0 (en) 1997-09-23 1998-09-21 New npy antagonists
PL98339617A PL339617A1 (en) 1997-09-23 1998-09-21 Novel antagonists of neuropeptide y
ARP980104740A AR017138A1 (es) 1997-09-23 1998-09-22 Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos.
IS5410A IS5410A (is) 1997-09-23 2000-03-20 Ný mótlyf taugapeptíðs Y (NPY)
NO20001483A NO20001483L (no) 1997-09-23 2000-03-22 Nye NPY-agonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds

Publications (1)

Publication Number Publication Date
SE9703414D0 true SE9703414D0 (sv) 1997-09-23

Family

ID=20408331

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds

Country Status (21)

Country Link
US (1) US6127414A (sv)
EP (1) EP1017672B1 (sv)
JP (1) JP2001517651A (sv)
KR (1) KR20010024220A (sv)
CN (1) CN1279666A (sv)
AR (1) AR017138A1 (sv)
AT (1) ATE228500T1 (sv)
AU (1) AU9288998A (sv)
BR (1) BR9812492A (sv)
CA (1) CA2303528A1 (sv)
DE (1) DE69809782T2 (sv)
EE (1) EE200000171A (sv)
IL (1) IL134993A0 (sv)
IS (1) IS5410A (sv)
NO (1) NO20001483L (sv)
PL (1) PL339617A1 (sv)
SE (1) SE9703414D0 (sv)
SK (1) SK3602000A3 (sv)
TR (1) TR200000785T2 (sv)
WO (1) WO1999015498A1 (sv)
ZA (1) ZA988353B (sv)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802075D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
US6312898B1 (en) * 1999-04-15 2001-11-06 Hormos Medical Oy, Ltd. Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
SE9902596D0 (sv) * 1999-07-06 1999-07-06 Astra Ab Pharmaceutically active compounds
EP1095933A1 (en) * 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
SE0101328D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Therapeutic treatment
EP1388537A1 (en) * 2001-05-15 2004-02-11 Taisho Pharmaceutical Co., Ltd Arginine derivatives
ATE462432T1 (de) 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
FR2864830B1 (fr) * 2004-01-06 2006-03-10 Centre Nat Rech Scient Procede de synthese sur support solide de composes peptidiques, notamment de composes peptidiques comportant un residu arginine
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
KR100689499B1 (ko) * 2005-10-26 2007-03-02 삼성전자주식회사 휴대단말기에서 키 설정 정보 디스플레이 방법
WO2007064272A1 (en) * 2005-11-29 2007-06-07 Astrazeneca Ab Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US20240226343A1 (en) * 2022-11-23 2024-07-11 Radionetics Oncology, Inc. Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5873821A (en) * 1992-05-18 1999-02-23 Non-Invasive Technology, Inc. Lateralization spectrophotometer
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544687A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544686A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2000501107A (ja) * 1996-01-09 2000-02-02 イーライ・リリー・アンド・カンパニー ベンズイミダゾリル神経ペプチドy受容体アンタゴニスト
EP0889034B1 (en) * 1996-03-21 2003-09-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives
EP1007073A4 (en) * 1996-06-04 2002-03-27 Synaptic Pharma Corp METHODS OF MODIFYING FOOD BEHAVIOR, COMPOUNDS USEFUL IN SAID METHODS, AND DNA ENCODING A HYPOTHALAMIC NEUROPEPTIDE Y / PEPTIDE YY Y5 RECEPTOR
CA2260983A1 (en) * 1996-07-23 1998-01-29 Charles A. Blum Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
JP2000515150A (ja) * 1996-07-23 2000-11-14 ニューロジェン・コーポレーション 置換ベンジルアミン誘導体:新規な種類の神経ペプチドy1特異的リガンド
US5985873A (en) * 1996-07-23 1999-11-16 Neurogen Corporation Certain substituted benzylamine derivatives a new class of Neuropeptide-Y1 specific ligands
WO1998007420A1 (en) * 1996-08-23 1998-02-26 Agouron Acquisition Corp. Neuropeptide-y ligands
EP0955293B1 (en) * 1996-12-03 2003-03-19 Banyu Pharmaceutical Co., Ltd. Urea derivatives
EP0945438B1 (en) * 1996-12-12 2003-03-05 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
DE69720038T2 (de) * 1996-12-13 2003-08-28 Banyu Pharmaceutical Co., Ltd. Aminopyrazolderivate
US6180653B1 (en) * 1996-12-16 2001-01-30 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
AU733883B2 (en) * 1997-02-04 2001-05-31 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
AU6267198A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amides as npy5 receptor antagonists
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO1998040356A1 (fr) * 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Medicaments contenant des derives d'aminopyridine comme ingredient actif
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists

Also Published As

Publication number Publication date
AR017138A1 (es) 2001-08-22
BR9812492A (pt) 2000-09-26
EE200000171A (et) 2001-04-16
WO1999015498A1 (en) 1999-04-01
IL134993A0 (en) 2001-05-20
TR200000785T2 (tr) 2000-09-21
SK3602000A3 (en) 2001-01-18
ATE228500T1 (de) 2002-12-15
IS5410A (is) 2000-03-20
ZA988353B (en) 1999-03-23
EP1017672A1 (en) 2000-07-12
AU9288998A (en) 1999-04-12
CN1279666A (zh) 2001-01-10
NO20001483L (no) 2000-05-23
US6127414A (en) 2000-10-03
CA2303528A1 (en) 1999-04-01
PL339617A1 (en) 2001-01-02
DE69809782T2 (de) 2003-07-17
KR20010024220A (ko) 2001-03-26
EP1017672B1 (en) 2002-11-27
DE69809782D1 (de) 2003-01-09
NO20001483D0 (no) 2000-03-22
JP2001517651A (ja) 2001-10-09

Similar Documents

Publication Publication Date Title
SE9703414D0 (sv) New compounds
PT1000035E (pt) 6-fenilfenantridinas substituidas
BG101112A (en) The use of heterocyclic compounds
BR9502708A (pt) Compostos bem como composiçao farmaceutica comprendendo os mesmos
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
BR9707233A (pt) Fenantridinas
TR199901653T2 (xx) Fitalazinonlar.
DE59509846D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DE59510370D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
FR2712591B1 (fr) Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
BG105710A (en) 5ht1 antagonists for antidepressant therapy
CO4410330A1 (es) Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida
ATE242236T1 (de) N-substituierte 3-azabicyclo(3.2.0)heptan- derivate als neuroleptika
ATE213731T1 (de) Chinoxalinderivate und ihre therapeutische verwendbarkeit
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
HUP0100781A2 (hu) A jóindulatú prosztata hiperplázia kezelésére alkalmas szubsztituált piridino aril piperazin-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
SE9902387D0 (sv) New pharmaceutically active compounds
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.
SE9902596D0 (sv) Pharmaceutically active compounds